$ABEO News Article - Abeona Therapeutics Announces Completion of Patient Follow-up in Pivotal Phase 3 VIITAL(TM) Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
https://marketwirenews.com/news-releases/abeo...41117.html